Interferons at age 50: past, current and future impact on biomedicine

@article{Borden2007InterferonsAA,
  title={Interferons at age 50: past, current and future impact on biomedicine},
  author={Ernest C. Borden and Ganes C Sen and Gilles Uz{\'e} and Robert H. Silverman and Richard M. Ransohoff and Graham R Foster and George R. Stark},
  journal={Nature Reviews. Drug Discovery},
  year={2007},
  volume={6},
  pages={975 - 990}
}
The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate… 
Interferon therapy of hepatitis C: molecular insights into success and failure.
TLDR
The outlook on novel therapeutics, including small molecule inhibitors of HCV proteins and immune modulators, is broadened by a glance at the exciting field of micro-RNAs that are likely to be implicated in viral replication and pathogenesis of CHC, thus representing a new therapeutic target.
Interferons α and β in cancer: therapeutic opportunities from new insights
  • E. Borden
  • Medicine
    Nature Reviews Drug Discovery
  • 2019
TLDR
New interferon-directed therapeutic opportunities, ranging from cyclic dinucleotides to genome methylation inhibitors, angiogenesis inhibitors, chemoradiation, complexes with neoantigen-targeted monoclonal antibodies, combinations with other emerging therapeutic interventions and associations with patient prognosis are discussed.
Recent advances in the anti-HCV mechanisms of interferon
TLDR
Current progress in understanding the mechanisms of IFN against HCV is reviewed, knowledge of induction of interferon signaling by HCV infection is summarized, and how interferons trigger anti-HCV activities as well as control the outcome of HCV infections is summarized.
Biological basis for a proper clinical application of alpha interferons.
TLDR
The data presented on the functional distinctions between IFN-alpha subtypes suggest that the commercially availableIFN- alpha preparations may differ in some biological, pharmacological and therapeutic aspects and that a wiser and more prudent use of the different IFN -alpha preparations may provide more therapeutic benefits to patients.
Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
TLDR
As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcome and mechanisms of refractoriness, new administration schedules are expected to provide a new life to this valuable cytokine.
Immunopharmacological consequences of immune responses to therapeutic interferon beta
TLDR
A systematic review was conducted to determine factors affecting the formation of neutralising antibodies against three different formulations of IFN-β Avonex™, Rebif™ and Betaseron/Betaferon™ and highlight the relative differences in immunogenicity risk.
Type I interferons: ancient peptides with still under-discovered anti-cancer properties.
TLDR
Current knowledge about the antitumor activity of type I IFNs is reviews the current knowledge, focusing on new potential strategies able to strengthen the antitalpine activity of these cytokines.
Development of resistance to biologic therapies with reference to IFN-β.
TLDR
In this review, reasons for the formation of ADAs, and particularly neutralizing antibodies (NAbs), are considered, with a focus on IFN-β as a well-studied example.
Interferon Beta: From Molecular Level to Therapeutic Effects.
TLDR
This chapter reviews the current knowledge on IFNβ from its structure, dynamic conformation, signaling pathway, and mechanism of action to its therapeutic effects and discusses immunogenicity and its relation to structural properties.
Interferon α in cancer immunoediting: From elimination to escape
  • P. Vidal
  • Medicine
    Scandinavian journal of immunology
  • 2020
TLDR
It is proposed that IFNα has dual opposing roles in cancer development based on the mutational status of its signalling components, which determines the expression of anti‐ or pro‐tumorigenic IFN‐stimulated genes (ISGs).
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 296 REFERENCES
Biological Properties of Recombinant  «-Interfà © rons : 40 th Anniversary of the Discovery of Interferons 1
IFNs were first described as potent antiviral agents 40 years ago, and recombinant IFN-a^ and IFN-a2h were approved for the treatment of hairy cell leukemia just 11 years ago. Today, a-IFNs are
Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases
TLDR
These IFN-αs have an activity profile that may result in an improved therapeutic index and, consequently, better clinical efficacy for the treatment of chronic viral diseases such as hepatitis B virus, human papilloma virus, HIV, or chronic hepatitis C.
Systemic interferon therapy of multiple sclerosis: the pros.
TLDR
It has been shown that the preparation of natural human alpha interferon used in this trial may lead to side effects in some individuals through the production of immune complexes (ICs), which were due to the generation of antibodies reacting with residual Sendai virus proteins used in the prepared IFN, and retained in the final formulation.
Antiviral Actions of Interferons
  • C. Samuel
  • Medicine, Biology
    Clinical Microbiology Reviews
  • 2001
SUMMARY Tremendous progress has been made in understanding the molecular basis of the antiviral actions of interferons (IFNs), as well as strategies evolved by viruses to antagonize the actions of
Interferons, immunity and cancer immunoediting
TLDR
The roles of the IFNs are discussed, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
TLDR
Recent developments in the understanding of the antiviral and immunoregulatory properties of IFN-alpha, the nature of the multisubunit IFn-alpha receptor, and the molecular mechanisms of signal transduction are reviewed.
Small ISGs coming forward.
  • P. Martensen, J. Justesen
  • Biology, Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2004
TLDR
This review focuses on three families of small intracellular and intrinsically nonsecreted proteins separated into groups according to their amino acid sequence similarity: theISG12 group (6-16, ISG12, and ISG 12-S), the 1-8 group (9-27/Leu13, 1- 8U, and 1-7D), and the ISG15 group (ISG15/UCRP).
Past, present, and future hepatitis C treatments.
  • G. Foster
  • Medicine
    Seminars in liver disease
  • 2004
TLDR
Pegylated interferons have improved pharmacokinetic profiles, may be administered once weekly, and are more effective than IFN is alone or in combination with ribavirin, and improves health-related quality of life during therapy compared with IFN-based therapy.
[Treatment of multiple sclerosis with interferons].
TLDR
The clinical use of beta interferon considering the cost and large treatment period, must be cautious, reserving it only for confirmed remitting-relapsing modalities of MS, and there is no clear cut evidence that beta interFERon is useful for chronic-progressive MS.
Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis
TLDR
Possible mechanisms and the role of ISGs involved in mediating apoptotic function of IFNs are emphasized.
...
1
2
3
4
5
...